Do SPM receptors undergo desensitization with chronic agonist treatment, preventing therapeutic priming?
PARTIALLY ADDRESSED
The debate highlighted receptor desensitization as a critical concern for SPM receptor priming therapy, but no definitive data exists on whether ALX/FPR2 and GPR32 follow typical GPCR desensitization patterns. This fundamental question determines the viability of chronic priming approaches.
Source: Debate session sess_sda-2026-04-01-gap-014 (Analysis: sda-2026-04-01-gap-014)
Priority: 0.90Domain: pharmacologyHypotheses: 0
📊 Landscape Analysis
Landscape Summary:
Do SPM receptors undergo desensitization with chronic agonist treatment, preventing therapeutic priming? is a 0.9 priority gap in pharmacology.
It has 0 linked hypotheses with average composite score 0.000.
Status: partially_addressed.
Key Unanswered Questions
What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?
Key Researchers
Colonna, Sevlever, et al. (TREM2 biology)
Clinical Trials
Do SPM receptors undergo desensitization with chronic agonist treatment, preventing therapeutic priming? — INVOKE-2 (completed)